AMAL THERAPEUTICS
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.
AMAL THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Life Science Neuroscience Therapeutics
Founded:
2012-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.amaltherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
45.34 M USD
Technology used in webpage:
SPF Amazon Google Apps For Business Microsoft Azure DNS Facebook Sharer Facebook Domain Verification GlobalSign Domain Verification Incapsula Nameshield
Current Advisors List
Current Employees Featured
Founder
Investors List
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - Amal Therapeutics
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series B - Amal Therapeutics
BioMedPartners
BioMedPartners investment in Series B - Amal Therapeutics
Schroder Adveq
Schroder Adveq investment in Series B - Amal Therapeutics
3B Future Health Fund
3B Future Health Fund investment in Series B - Amal Therapeutics
VI Partners
VI Partners investment in Series B - Amal Therapeutics
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series B - Amal Therapeutics
Schroder Adveq
Schroder Adveq investment in Series B - Amal Therapeutics
BioMedPartners
BioMedPartners investment in Series B - Amal Therapeutics
3B Future Health Fund
3B Future Health Fund investment in Series B - Amal Therapeutics
Official Site Inspections
http://www.amaltherapeutics.com
- Host name: 45.60.72.30
- IP address: 45.60.72.30
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Amal Therapeutics"
About us - amaltherapeutics.com
AMAL Therapeutics (AMAL) is a biotech, developing unique therapeutic vaccines and a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. Our aim is to overcome the challenges around …See details»
BI Acquires AMAL Therapeutics | Boehringer Ingelheim US
Tel: +44 (0) 207 457 2020 [email protected]. Media Contacts. Linda Ruckel 900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877. Phone +1 (203) 791-6672. …See details»
Amal Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal …See details»
Amal Therapeutics SA – Swiss Biotech
AMAL Therapeutics is a Swiss biotech developing therapeutic vaccines, and aiming at overcoming the challenges around effective anti-cancer therapy by stimulating the immune …See details»
Amal Therapeutics 2025 Company Profile: Valuation, Investors ...
Amal Therapeutics General Information Description. Developer of therapeutic vaccines designed to facilitate oncology treatment. The company's peptide-based vaccines generate a cellular …See details»
Amal Therapeutics SA - Genf, Switzerland - bionity.com
Amaltherapeutics.com. Contact. Profile Products News. Contact. About Amal Therapeutics. Amal Therapeutics SA is a privately held Swiss biotech start-up company and a spin-off from the …See details»
Amal Therapeutics - Craft
Amal Therapeutics is a biotech company, which engages in the research and development of therapeutic vaccines in oncology. The Company uses its cell penetrating peptide platform to …See details»
AMAL Therapeutics - Association GEnevoise pour les Métiers de …
Technology Platform. AMAL Therapeutics developed a versatile and flexible recombinant protein vaccine technology platform called KISIMA Ò.KISIMA is a three-component chimeric protein …See details»
AMAL THERAPEUTICS SA Company Profile - Dun & Bradstreet
AMAL THERAPEUTICS SA Company Profile | Genève, GENÈVE, Switzerland | Competitors, Financials & Contacts - Dun & BradstreetSee details»
amaltherapeutics.com - Transforming the prospects of cancer …
Oct 20, 2022 Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccinesSee details»
AMAL Therapeutics - Overview, News & Similar companies
Jul 15, 2019 AMAL Therapeutics contact info: Phone number: +41 223794688 Website: www.amaltherapeutics.com What does AMAL Therapeutics do? AMAL Therapeutics SA is a …See details»
Amal Therapeutics (Exit) - HTGF
About the company Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using …See details»
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly ...
Jul 15, 2019 Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform. Ingelheim am Rhein, …See details»
AMAL Therapeutics acquired by Boehringer Ingelheim for its …
Jul 15, 2019 Boehringer Ingelheim acquired all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class …See details»
AMAL Therapeutics - Unité de formation des apprentis (UFA)
Technology Platform. AMAL Therapeutics developed a versatile and flexible recombinant protein vaccine technology platform called KISIMA Ò.KISIMA is a three-component chimeric protein …See details»
Careers - amaltherapeutics.com
We are located on the campus of the University of Geneva Switzerland giving us ready access to state of the art laboratory equipment. Our talented team is made of experts in cellular and …See details»
Therapeutic Vaccines - amaltherapeutics.com
Cellular response specific for tumour cells. The main goal of a therapeutic cancer vaccine is to generate a cellular immune response including activation of killer T cells (also called cytotoxic …See details»
Joint Team Effort Succeeds in Advancing First-in-Cass Triple ...
Joint Team Effort Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer. AMAL Therapeutics and ViraTherapeutics, in …See details»
News - amaltherapeutics.com
Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research team, in collaboration with Prof. Guido Wollman’s lab at the …See details»
Unique cancer vaccines target immunotherapy - Nature
Swiss-based AMAL Therapeutics is developing KISIMA, a unique protein-based immunization platform capable of producing single therapeutic vaccines for immunotherapy and beyond.See details»